Stay updated with breaking news from Device Exemption. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SELUTION SLR, MedAlliance\'s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA).
GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its
Geneva [Switzerland], August 10 (ANI/PRNewswire): SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA).
Get latest articles and stories on Business at LatestLY. SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). Business News | MedAlliance SELUTION SLR Receives Second FDA IDE Approval.
GENEVA, Aug. 9, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational De...